The
slide to be stained for Thyroid transcription factor-1
(TTF1) comprised:
1. Lung adenocarcinoma, 2. Lung carcinoid, 3. Lung, 4. Thyroid gland,
5. Liver.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a TTF1 staining as optimal included:
- A strong, distinct nuclear staining of the
pneumocytes type II and the Clara cells in the lung.
- A strong, distinct nuclear staining of all
the follicular cells and C-cells in the thyroid gland.
- A strong nuclear staining of the majority
of the neoplastic cells in the lung adenocarcinoma and at least a
weak to moderate, distinct nuclear staining of the majority of
the neoplastic cells of the lung carcinoid.
No staining of other cells should be seen
except a granular cytoplasmic reaction with mAb clone
8G7G3/1.
99 laboratories submitted stains. At the assessment 15 achieved optimal marks (15 %), 9
good (9 %), 59 borderline (60 %) and 16 (16 %) poor marks.
The following Abs were used:
mAb clone 8G7G3/1 (Dako n=56; NeoMarkers n=11; Ventana n=6; Eurodiagnostica, n=1)
mAb clone SPT24 (Novocastra, n=25)
Optimal staining for TTF1 in this assessment was only
obtained with the mAb clone SPT24 (15 out of 25 laboratories
= 60%).
The protocols giving an optimal
result with SPT24 were all based on heat induced epitope retrieval (HIER) using
either Tris-EDTA/EGTA pH 9 (12 out of 16), Cell
Conditioning 1 (CC1 Ventana; 1 out of 1), Target
Retrieval Solution (TRS Dako pH 9.9; 1 out of 1) or
Bond Epitope Retrieval Solution 2 (BERS 2, Vision
BioSystem; 1 out of 1). The Ab was used in the
range of 1:40 – 1:500 depending on the total sensitivity of the protocol employed. Using these settings 19 out of 20
laboratories (95%) produced a sufficient staining (optimal or good).
With mAb clone 8G7G3/1 only two out of 74 laboratories (3%)
were marked as good while the rest obtained borderline or poor marks
- primarily due to a false negative reaction of
the lung carcinoid but also
due to a generally weaker nuclear reaction in cells expected to
stain, as well as cytoplasmic cross
reaction, not only in liver cells but also in some tumours.
The two protocols giving good marks were based on efficient
HIER and a highly sensitive detection system. In these two cases the
carcinoid showed an unequivocal nuclear reaction, but at the same
time a strong cytoplasmic reaction (due to Ab cross reaction).
If the lung carcinoid were excluded from the assessment, 59 out 74
(80%) laboratories using the mAb clone 8G7G3/1 achieved a sufficient
mark.
The most frequent causes of an insufficient staining were:
- Less successful primary Ab
- Too low concentration of the primary Ab
- Insufficient HIER (Citrate pH 6)
In the assessment the prevalent feature of the insufficient results
was a false negative staining of the lung carcinoid with clone 8G7G3/1.
Insufficient results with the SPT24 were characterized by a generally
too weak reaction of the cells expected to be demonstrated.
Normal lung and thyroid are suitable for control tissue: The nuclear
staining should be as strong as possible without
significant cytoplasmic reaction. Preferentially, tissue with low antigen content should also
be included such as selected cases of well-differentiated pulmonary
carcinoid, provided that clone SPT24 is used.
TTF1 was also assessed in
run 9, 2003, where 63 laboratories
participated out of which 38 (60%) obtained a
sufficient mark. In run 9 both the mAb clone 8G7G3/1 and the
clone SPT24 could give optimal results (the slide contained a lung carcinoid that also
could be stained with clone 8G7G3/1). However, also in that
run the pass rate of
SPT24 was superior to that of 8G7G3/1 (see table).
| |
Run 9 2003 |
Run 19 2007 |
Total |
| |
Protocols |
Sufficient |
Protocols |
Sufficient |
Protocols
analyzed |
Sufficient |
| MAb clone 8G7G3/1 |
53 |
28 |
74 |
2 |
127 |
30 (24%) |
| MAb clone SPT24 |
10 |
10 |
25 |
22 |
35 |
32 (91%) |
Conclusion
Based on the two assessments it appears that the mAb clone SPT24 is the most robust and sensitive
marker for the demonstration of TTF1.
The mAb clone 8G7G3/1 has a lower sensitivity especially
for carcinoid tumours. Please carefully read the TTF1
epitope description as TTF1 occurs in more tumour types than
previously described, when using clone SPT24. Efficient HIER is
mandatory. |